Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -44.75% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
The market has gone on a wild yet profitable ride so far this year, and Kevin Matras believes the rest of 2025 could be even more spectacular. Discover how to take advantage of what's shaping up to be another year of double-digit returns.